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Purpose: To evaluate the use of docetaxel in very elderly men with metastatic castration-resistant
prostate cancer (mCRPC) treated in routine clinical care.
Methods: A retrospective case series of men with mCRPC aged 80 years and treated with docetaxel
between July 2006 and June 2012 at three community hospitals in Melbourne, Australia.
Results: Twenty patients were identiﬁed, with a median age of 83 years (range 80e93 years). Aside from
one patient treated weekly, all patients were treated with a 3-weekly regimen of docetaxel with a
median of six cycles (range 1e10 cycles) delivered. Eight patients (40%) had an initial dose reduction and
11 patients (55%) had subsequent dose delays or reductions. Eight patients (40%) completed planned
treatment. Grade 3/4 hematologic toxicity was observed in nine patients (45%), and ﬁve patients (25%)
were admitted to hospital with chemotherapy-related complications. Prostate-speciﬁc antigen (PSA)
response was assessable for 16 patients, of whom nine (56%) had a PSA response of 50% and one (6%)
had a PSA-complete response. The median overall survival in this cohort was 13.4 months.
Conclusions: Very elderly patients (80 þ years) with mCRPC are infrequently included in clinical trials,
yet the use of chemotherapy in this population is likely to increase. Our series demonstrates signiﬁcant
response rates to docetaxel chemotherapy, but that a substantial number of patients had treatment-
related complications. This highlights the need for careful patient selection and optimization of
chemotherapy dosing.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is the second most commonly diagnosed ma-
lignancy in men worldwide.1 Approximately three-quarters of the
registered cases occur in developed countries, with Australia and
New Zealand recording the highest incidence rates. It is predomi-
nantly a disease of the elderly, with incidence and mortality
increasingwith age. In an analysis of menwith prostate cancer from
the Surveillance, Epidemiology, and End Results database, elderly
patients were more likely to present with metastatic disease at
diagnosis and those aged >75 years accounted for over half of
prostate cancer-related deaths.2cology, The Royal Melbourne
.
ng).
ier B.V. on behalf of Prostate InteProstate cancer is typically hormone-responsive, however, once
castration resistance sets in, median overall survival is generally <2
years.3 Docetaxel was the ﬁrst agent to offer a survival advantage in
metastatic castration-resistant prostate cancer (mCRPC). It has
been shown in two randomized phase III trials to improve survival
and quality of life compared to mitoxantrone.4,5 Subsequently, 3-
weekly docetaxel at 75 mg/m2 has become the current standard
ﬁrst-line treatment for mCRPC.
In elderly patients, a signiﬁcant concernwith this regimen is the
risk of serious toxicity, in particular, myelosuppression and sepsis.
In a subgroup analysis of the landmark TAX327 trial, men aged75
years had signiﬁcantly higher rates of infection and required more
frequent dose reductions than younger patients.6
This retrospective study was performed to review the use of
docetaxel in very elderly men (aged  80 years) with mCRPC
treated in a community setting. In particular, the aims were tornational. This is an open access article under the CC BY-NC-ND license (http://
H.-L. Wong et al. / Prostate International 3 (2015) 42e46 43explore dosing practices in routine clinical care, and the tolerability
and efﬁcacy of docetaxel in this group of patients.
2. Methods
2.1. Patients
Men with mCRPC aged 80 years and treated with docetaxel
between 1 July 2006 and 30 June 2012 were identiﬁed from the
databases of three hospitals in Melbourne, Australia. Clinicopath-
ologic, treatment, and response data were extracted from a retro-
spective review of hospital charts and pharmacy dispensing
records.
2.2. Variables
Baseline patient characteristics of interest were Eastern Coop-
erative Oncology Group (ECOG) performance status, and the pres-
ence of the following comorbidities: ischemic heart disease,
chronic pulmonary disease, diabetes, renal impairment (estimated
glomerular ﬁltration rate < 60 mL/min) and cognitive or mood
disorders. Disease characteristics at baseline were obtained,
including time to castration resistance, Gleason score, sites of
metastatic disease, and the presence of pain requiring regular
opioid analgesia.
Initial planned docetaxel doses and schedules were recorded,
along with subsequent dose modiﬁcations and reasons for dis-
continuing treatment. Hematologic toxicities and treatment-
related complications resulting in hospital admissions were
noted. Serum prostate-speciﬁc antigen (PSA) was recorded pre-
treatment and post-treatment to calculate the best PSA response.
Symptomatic response to treatment was recorded where appli-
cable. Overall survival was calculated from the ﬁrst dose of doce-
taxel to the date of death or last follow up.
2.3. Statistical analysis
Individual patient data were tabulated and summarized using
descriptive statistics. Overall survival was calculated using the
KaplaneMeier method. All statistics were calculated using Graph-
pad Prism V6.01 (GraphPad Software, Inc., La Jolla, CA, USA).Table 1
Baseline characteristics of 20 patients aged 80 years who received docetaxel for metas
Patient Age (y) ECOG Number of
comorbidities
Time to castration
resistance (y)
G
sc
1 85 1 2 10 1
2 80 N/A 2 1 1
3 93 1 0 8 N
4 83 1 2 13 N
5 87 1 2 5 8
6 80 1 2 4 7
7 80 1 1 6 8
8 82 1 1 17 N
9 83 1 1 11 N
10 88 1 1 3 N
11 82 1 0 3 9
12 83 1 0 4 N
13 81 N/A 2 7 7
14 82 N/A 0 4 6
15 80 N/A 2 9 8
16 80 0 2 16 7
17 80 N/A 2 2 9
18 83 N/A 1 4 7
19 85 0 0 12 7
20 87 N/A 1 3 7
ECOG, Eastern Cooperative Oncology Group performance status; N/A, data not available;2.4. Ethics approval
Approval for this study was obtained from the research and
ethics committees of the participating institutions. Patient consent
was not obtained due to the retrospective nature of the study, and
no identifying or sensitive information is presented.3. Results
3.1. Patient characteristics
Twenty men were identiﬁed with a median age of 83 years
(range 80e93 years). Patient and disease characteristics are pre-
sented in Table 1. ECOG performance status was documented for 13
(65%) patients, who were all of a good performance status of ECOG
0 or 1. Fifteen (75%) patients had at least one comorbid condition,
with renal impairment (n ¼ 11) and ischemic heart disease (n¼ 10)
the most commonly observed.
Eleven (55%) patients had bone-only disease, two (10%) patients
had visceral metastases, and one (5%) patient had local recurrence
only. Pretreatment serum PSA was available for all but one patient,
with a median of 140 ng/mL (range 13e1810 ng/mL). Three (15%)
patients had pain requiring daily opioid analgesia.3.2. Treatment delivery
Treatment details are presented in Table 2. Aside from one pa-
tient treated weekly, all received the standard 3-weekly regimen of
docetaxel 75 mg/m2, with a median of six cycles received (range
1e10). All patients also received prednisolone 10 mg/day. Eight
(40%) patients commenced treatment with an initial dose reduction
and 11 (55%) patients required subsequent dose modiﬁcations,
including three patients who had commenced treatment at a
reduced dose.
Eight (40%) patients completed their planned treatment, with
six and two patients receiving six and 10 cycles, respectively. Two
(10%) patients discontinued treatment early for toxicity, ﬁve (25%)
patients due to other medical problems, and four (20%) patients
stopped due to disease progression.tatic castrate-resistant prostate cancer.
leason
ore
Baseline
PSA (ng/mL)
Metastatic
disease sites
Pain requiring daily
opioid analgesia
0 113 Bone Yes
0 869 Bone and lymph nodes N/A
/A 1760 Bone No
/A 524 Bone and lymph nodes No
61 Bone Yes
22 Bone No
13 Lymph nodes No
/A 112 Bone No
/A N/A Bone No
/A 18 Visceral Yes
125 Bone No
/A 1810 Bone and visceral No
71 Lymph nodes No
372 Bone No
107 Local recurrence No
233 Bone N/A
437 Bone and lymph nodes No
339 Bone and lymph nodes No
161 Bone No
140 Bone No
PSA, prostate speciﬁc antigen.
Table 2
Treatment delivery, toxicities, and prostate speciﬁc antigen (PSA) response of 20 patients aged  80 years who received docetaxel for metastatic castrate-resistant prostate
cancer.
Patient Docetaxel
regimena)
Initial dose
reduction
Number
of cycles
received
Subsequent
dose reduction
or treatment delay
Reason for discontinuing
treatment
Hospital admission for
chemotherapy-related
complication
Grade 3
hematologic
toxicity
Best PSA response
1 3-weekly No 6 Yes Treatment completed Yes Yes <50% decline
2 3-weekly Yes 3 Yes Other medical problem Yes No 50% decline
3 3-weekly Yes 6 Yes Treatment completed No Yes <50% decline
4 3-weekly Yes 1 N/A Other medical problem No No 50% decline
5 3-weekly Yes 6 No Treatment completed No No 50% decline
6 3-weekly Yes 10 Yes Treatment completed No No N/A
7 3-weekly No 8 Yes Progressive disease Yes Yes 50% decline
8 3-weekly No 9 Yes Progressive disease Yes Yes 50% decline
9 3-weekly Yes 3 No Unclear No No N/A
10 3-weekly Yes 2 No Other medical problem No No Progression
11 3-weekly No 8 Yes Progressive disease No Yes N/A
12 3-weekly Yes 2 No Other medical problem No Yes N/A
13 3-weekly No 6 No Toxicity No No 50% decline
14 3-weekly No 6 Yes Treatment completed No Yes <50% decline
15 Weekly No 1 N/A Other medical problem Yes No <50% decline
16 3-weekly No 8 No Toxicity No No 50% decline
17 3-weekly No 6 Yes Progressive disease No No Progression
18 3-weekly No 6 Yes Treatment completed No Yes 50% decline
19 3-weekly No 10 No Treatment completed No No <50% decline
20 3-weekly No 6 Yes Treatment completed No Yes 50% decline
N/A, data not available; PSA, prostate speciﬁc antigen.
a) Docetaxel regimens: 3-weekly, 75 mg/m2 every 21 days; weekly, 35 mg/m2 on Days 1 and 8 every 21 days.
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Grade 3 or 4 hematologic toxicity was observed in nine (45%)
patients, including six patients with Grade 3 or 4 neutropenia. Five
(25%) patients were admitted to hospital with chemotherapy-
related complications, with three of these due to infections.3.4. Efﬁcacy
PSA response was assessable for 16 patients (Table 2). Of these,
nine (56%) patients had a PSA response of 50% and one (6%) pa-
tient had a PSA-complete response. All three patients who had pain
requiring opioid analgesia had improvement in their pain after
commencing treatment.
Summary data for initial dose reduction, toxicity, and PSA
response for patients stratiﬁed by number of comorbidities and
number of chemotherapy cycles are presented in Fig. 1.
Follow up was recorded up to 30 June 2014, where two patients
were lost to follow up and all remaining patients had died. The
median overall survival was 13.4 months and 1-year survival was
64.6%. One-year survival in patients with 50% PSA response was
89%, compared to 43% in patients with <50% PSA response
(P ¼ 0.081; Fig. 2).4. Discussion
The management of elderly patients with mCRPC remains
challenging due to a paucity of prospective randomized trial data to
guide clinical decision-making. Subgroup analyses of clinical trial
participants6 and retrospective studies7 suggest that older patients
treated with docetaxel derive similar beneﬁts to younger patients,
although at a cost of potentially increased toxicity.
In the landmark TAX327 study in which approximately 20% of
patients were at least 75 years of age, the overall survival beneﬁt
from 3-weekly docetaxel was equivalent across age groups, with
hazard ratios of 0.81 and 0.77 for men aged 68 years and >68
years, respectively.5 Even with an older age cutoff of 75 years, the
hazard ratio was maintained at 0.80. Measures of clinical beneﬁt,such as improvements in quality of life and pain responses, were
also comparable among the under 65 years, 65e74 years, and 75
years age groups.6
However, older patients appear to be more susceptible to
treatment-related adverse events, with those aged 75 years
having signiﬁcantly higher rates of infection of any grade and
requiring dose reductions more frequently than those in the <65
years and 65e74 years age groups.6 Similar trends were seen in a
small retrospective study of 51 Japanese patients treated with
docetaxel 70 mg/m2 every 3 weeks, with higher rates of Grade 3e4
neutropenia in the 20 patients aged 75 years (70% vs. 48% of
patients <75 years, P ¼ 0.16).7
In our series, 40% of very elderly (age  80 years) patients were
able to complete planned treatment; however, a substantial pro-
portion required dose modiﬁcations, highlighting the difﬁculties in
determining optimal dosing in patients of advanced age. Similar
ﬁndings have been reported in a retrospective series of 159
Japanese patients aged 75 years who received docetaxel in the
community setting, in which 87% of patients required dose
modiﬁcations.8
One strategy when administering docetaxel to older patients is
to use weekly scheduling, which is generally perceived to be better
tolerated due to lower rates of hematologic toxicity compared
to the standard 3-weekly regimen. In a post hoc analysis of the
patients aged 75 years in the TAX327 study, there was no differ-
ence in the type or frequency of toxicities between the weekly
and 3-weekly docetaxel arms, although signiﬁcantly more dose
reductions were required in patients receiving 3-weekly treat-
ment.6 By contrast, a retrospective multicenter French study of 175
patients aged 75 years, including 57 (32.6%) patients aged  80
years, showed signiﬁcantly higher rates of febrile neutropenia
among those who received standard 3-weekly docetaxel, whereas
those who received weekly treatment experienced more Grade
3e4 fatigue and were more likely to stop chemotherapy because of
toxicity (30% vs. 8%), possibly due to a higher proportion of older
and poor performance status patients in this group.9
A fortnightly treatment schedule has also been prospectively
explored in a European multicenter trial of 361 patients (median
Fig. 1. Summary data for patients stratiﬁed by number of comorbidities and number of chemotherapy cycles. Proportion of patients: (A) requiring initial dose reduction, (B) with 
Grade 3 hematologic toxicities; and (C) with 50% prostate-speciﬁc antigen (PSA) response.
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weeks or 75 mg/m2 every 3 weeks.10 Patients receiving fortnightly
treatment had signiﬁcantly fewer neutropenic infections (6% vs.
24%, P ¼ 0.002), with no difference observed in nonhematological
toxicities or quality of life. In addition, 2-weekly treatment wasFig. 2. One-year overall survival for patients with prostate-speciﬁc antigen (PSA)
response  50% versus < 50%. One-year overall survival proportions: patients with
50% PSA response ¼ 89%, Patients with <50% PSA response ¼ 43%, P ¼ 0.081.associated with longer time to treatment failure (hazard ratio
1.3, 95% conﬁdence interval 1.1e1.6) and longer overall survival
(median 19.5 months vs. 17 months, P ¼ 0.021).
Treatment efﬁcacy in our patient series is difﬁcult to determine
due to the retrospective nature of this study and the absence of a
control group. However, just over half of the patients derived
clinical beneﬁt from treatment in terms of 50% PSA response or
improvement in pain. We also observed that patients who had a
PSA response of 50% had longer overall survival than those who
did not, consistent with previous reports.11
In recent years, multiple new agents have been shown to
improve survival in patients with mCRPC. These include chemo-
therapy (cabazitaxel),12 hormonal agents targeting androgen
biosynthesis (abiraterone)13,14 or the androgen receptor (enzaluta-
mide),15,16 and radium-223, an alpha emitter.17 Although optimal
treatment sequencing is not known, hormonal agents are an
attractive alternative to chemotherapy in elderly patients due to the
lower rates of myelosuppression and sepsis. In post hoc subgroup
analyses of the phase III studies of abiraterone18 and enzaluta-
mide,19 both agents were well tolerated in patients aged75 years,
although older patients treated with abiraterone experienced
higher rates of cardiac arrhythmias and peripheral edema than
those aged <75 years.17
It is well recognized that the elderly are a particularly het-
erogeneous population and patients enrolled in clinical trials are
not always representative of real world practice. This is reﬂected
in the International Society of Geriatric Oncology guidelines,
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vidual health status independently of chronological age.20 The
consensus recommendation is that patients undergo screening
for comorbidities, dependence, and malnutrition in order to be
classiﬁed as “healthy”, “vulnerable”, or “frail”, where vulnerable
and frail patients may be considered for treatment after medical
intervention. This concept has been embraced in novel clinical
trials designed speciﬁcally for older patients, such as the
GERICO10-GETUG P03 trial which randomized mCRPC patients
aged 75 years and classiﬁed as “vulnerable” or “frail” after
comprehensive geriatric assessment to weekly or 3-weekly
docetaxel, with the primary objective to examine the feasibility
of either regimen.21
There are several limitations to our case series. As with all
retrospective studies, data for some patients were incomplete and
nonhematologic toxicities were difﬁcult to capture. In addition, we
did not record data on postdocetaxel treatment. However, this
small series highlights the complexities of treating very elderly
patients with mCRPC in routine practice.
In conclusion, selected ﬁt elderly patients appear to tolerate
docetaxel and derive clinical beneﬁts from treatment, however,
optimal dosing remains unclear, because pharmacokinetic changes
with aging could potentially alter drug exposure and metabolism.
New hormonal agents such as abiraterone and enzalutamide are
attractive alternatives in elderly patients due to lower rates of
myelosuppression, although optimal treatment sequencing is not
yet known. Comprehensive geriatric assessment is likely to be
helpful in identifying patients at risk of increased toxicity, however,
it is time-consuming and difﬁcult to implement in a busy oncology
practice.Conﬂicts of interest
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